Liquid Biopsy Market Overview
The global liquid biopsy market size is expected to witness extensive growth in the coming years due to the advent of technological innovations to develop minimal invasive biopsy testing, global rise in prevalence of cancer and associated research. Among different product & services, the largest market is for assay kits, globally, due to the increase in adoption of the tests over classical biopsy testing, and the wide application it renders. The wide adoption has led to frequent usage of assay kits in comparison to the other offerings such as instruments and services.
Different circulating biomarkers used in liquid biopsy include circulating tumor cells (CTCs), circulating tumor DNA (CTDNA), cell-free DNA, extracellular vesicles (EVs), and others. Among the available circular biomarkers, the extracellular vesicles are anticipated to be the fastest-growing segment during the forecast period. This is due to the growing interest in EV research from biofluids that includes samples such as blood and urine for diagnostic and therapeutic monitoring.
Among the different applications, therapy selection is the largest application area of liquid biopsy, as it allows the evaluation of metastasis in real-time and monitoring of the actual treatment response.
The clinical indications of the liquid biopsy are cancer and non-cancer application. The liquid biopsy market is expected to witness the fastest growth for non- cancer application during the forecast period, mainly due to the procedure involved in noninvasive prenatal testing (NIPT), thereby identifying genetic abnormalities. Also, NIPT is replacing the risk associated with amniocentesis in critical cases of pregnancy, that will further enhance the growth of the market.
Reference laboratories, hospitals and physician laboratories, and academic and research centers, and others are the end users of liquid biopsy. Among these, the reference laboratories are the largest end user of liquid biopsy, due to the increase in sample outsourcing to these laboratories for testing and analysis.
North America is the largest market for liquid biopsy products and services, globally, mainly due to factors such as the presence of large number of academic and research institutes, and availability to technologically advanced products. Asia-Pacific is expected to witness the fastest growth for the liquid biopsy market during forecast period. The major factors driving its growth are increasing demand of minimally invasive procedures, rise in prevalence and new cases of cancer, and the development of healthcare infrastructure as a result of government expenditure in the region.
Liquid Biopsy Market Dynamics
Growth Drivers & Restraints
Various factors leading to the growth of the liquid biopsy industry include the rise in number of new cases of cancer and the growing prevalence of the disease, globally. The market is also driven by the rise in preference to minimally invasive procedures in comparison to the conventional methods, and the government expenditure on healthcare with focus on cancer research worldwide. The technological advancements, and increasing demand for personalized medication will also support the growth of the industry. However, certain factors such as concerns related to the sensitivity and specificity of the obtained results are hindering the growth of the market.
Opportunities
The liquid biopsy industry provides immense opportunities to the key players, as it gives faster results and can also be a cheaper option over the conventional method. Moreover, it has become more clinically useful in recent years due to the ability to pair tests on CTCs with genomic tests. Subsequently, the key players are also exploring opportunities by leveraging their precedence in technological advancement.
Liquid Biopsy Market Competitive Landscape
The growing partnerships and recent acquisitions are expected to increase the liquid biopsy market share of key players in the coming years.
For instance, in April 2017, Menarini-Silicon Biosystems, Inc. acquired all the assets and relevant business related to the CELLSEARCH Circulating Tumor Cell System from Janssen Diagnostics, LLC. CELLSEARCH Circulating Tumor Cell Test is the first USFDA clinically approved blood test for detecting and enumerating CTCs to help manage patients with metastatic breast, prostate, and colorectal cancers. The test also received clearance from the China Food and Drug Administration for the use in monitoring metastatic breast cancer patients. With the acquisition, Menarini-Silicon Biosystems, Inc. has for the first time entered into the U.S. diagnostic market.
Some of the other major players in the global market include Qiagen N.V., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc, Trovagene, Inc., Guardant Health, Inc., Genomic Health, Inc., MDxHealth SA, and F. Hoffmann-La Roche Ltd.
Liquid Biopsy Market Segmentation
By Product & Services
- Assay Kits
- Instruments
- Services
By Circulating Biomarker
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (CTDNA)
- Cell-Free DNA
- Extracellular Vesicles (EVs)
- Others
By Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
By Clinical Indication
- Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Others
- Non-cancer Application
By End User
- Reference Laboratories
- Hospitals and Physician Laboratories
- Academic and Research Centers
- Others
By Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- Rest of MEA
